Fla. Admin. Code R. 2-40.007

Current through Reg. 50, No. 222; November 13, 2024
Section 2-40.007 - Rescheduling of a Drug Product in Finished Dosage Formulation That Has Been Approved by the U.S. Food and Drug Administration That Contains Cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1, 3-benzenediol) Derived from Cannabis and No More Than 0.1 Percent (w/w) Residual Tetrahydrocannabinols

Under the authority of section 893.0355, Florida Statutes, a drug product in finished dosage formulation that has been approved by the U. S. Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1, 3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual Tetrahydrocannabinols, is hereby rescheduled from a Schedule I to a Schedule V controlled substance.

Fla. Admin. Code Ann. R. 2-40.007

Rulemaking Authority 893.0355 FS. Law Implemented 893.0355 FS.

Adopted by Florida Register Volume 45, Number 015, January 23, 2019 effective 2/7/2019.

New 2-7-19.